Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088634 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00088634 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 180 participants.
The verdict
NCT00088634, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia
Interventions
- DRUG Placebo
- DRUG Lurasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2004-05 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088634
The ClinicalTrials.gov registry entry for NCT00088634 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00088634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088634 about?
NCT00088634 is a clinical study titled "A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia". A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia
What is the current status of trial NCT00088634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2004-05. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00088634?
The interventions under investigation include: Placebo (DRUG), Lurasidone (DRUG).
Who is sponsoring clinical trial NCT00088634?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.